Gestational diabetes in focus: What the 2026 ACC/AHA dyslipidemia guideline means for lifelong cardiovascular prevention

Why this update matters 

The 2026 ACC/AHA dyslipidemia guideline update moves gestational diabetes mellitus (GDM) from background history to a reproductive risk marker that informs long-term cardiovascular prevention in adults without established disease. It also reflects changes to risk assessment, including broader recognition of reproductive risk markers and refinements to how atherosclerotic cardiovascular disease (ASCVD) risk is estimated and categorized.  

Compared with earlier guidance, the 2026 update expands the range of reproductive risk markers and lowers risk thresholds, meaning more patients may be considered for earlier intervention. Alongside these changes, the guideline highlights a small set of tests—lipoprotein(a), apolipoprotein B, and coronary artery calcium—that add context when standard measures leave questions unanswered. 

In 2026, pregnancy history moves from archival to actionable in ASCVD prevention.  

GDM in brief 

Gestational diabetes is glucose intolerance first identified during pregnancy, typically in the second or third trimester,¹ and is distinct from diabetes that predates conception. It is driven by pregnancy-related hormonal changes, including those from the placenta, that affect insulin response and can lead to elevated blood glucose levels during prenatal care. Most professional groups recommend routine screening in mid-pregnancy, with earlier evaluation for those at higher risk.  

Beyond short-term obstetric concerns, a history of GDM is linked with higher lifetime cardiometabolic risk,² which is why it appears in the new guideline as a risk-enhancing reproductive marker for cardiovascular prevention.  

What the evidence shows about GDM and later cardiovascular risk 

A growing body of longitudinal research links GDM with higher rates of cardiovascular events years after delivery, even when accounting for whether type 2 diabetes develops later. Meta‑analyses pooling large populations report an approximately 40% higher risk of outcomes such as heart attack and stroke in mothers with prior GDM compared with those without GDM.³ This signal underpins why GDM now sits among reproductive risk markers in the 2026 guideline.  

Because pregnancy can unmask lifelong cardiometabolic patterns, a contemporary risk estimate gives context to that history and helps frame prevention conversations after delivery. 

Why GDM belongs in prevention conversations today 

The writing committee identifies adverse pregnancy outcomes (APOs)—including gestational diabetes, hypertensive disorders of pregnancy, preterm delivery, growth-restricted infants, and pregnancy loss—as risk enhancers. These are not standalone indications, but factors that help clinicians and patients interpret risk more personally and understand long-term trajectory, even when symptoms are not yet apparent. Reproductive history is now considered alongside current lipids, blood pressure, kidney and metabolic data, and lifestyle in prevention discussions. 

PREVENT in one paragraph 

The guideline continues to use the American Heart Association (AHA) PREVENT ASCVD equations, with updates that expand their use to adults aged 30–79 years and refine the definitions of risk categories. These changes mean more patients may meet thresholds for preventive intervention, especially when additional risk enhancers are present. 

PREVENT provides calibrated 10-year, and optional 30-year, estimates and a consistent framework for discussing risk.⁴ You can explore the model at the AHA’s PREVENT calculator.  

When numbers alone are not enough, a few well-chosen tests can bring clarity without adding complexity.  

Three tests that add context

Pregnancy and postpartum: Scope & safety notes 

The dyslipidemia guideline reiterates longstanding principles for reproductive age care: Statins are generally avoided during pregnancy and lactation, bile acid sequestrants may be considered in pregnancy if LDL lowering is necessary because they are not systemically absorbed. In cases of severe triglyceride elevation during pregnancy, the document discusses targeted options alongside nutrition therapy to reduce pancreatitis risk and avoid complications such as hypoglycemia. These points keep safety front-of-mind while the broader prevention discussion proceeds over the life course.  

Glycemic surveillance after GDM, including blood sugar monitoring and long-term diabetes prevention, remains under diabetes and obstetric guidance. For those details, clinicians can consult ADA Standards: Management of Diabetes in Pregnancy. The dyslipidemia guideline complements that work by clarifying lipid-focused prevention themes so that obstetrics, primary care, and cardiology can align.  

The cardio-obstetrics lens and why transitions of care matter 

The AHA has highlighted APOs (including GDM) as lifelong cardiovascular “red flags,” and called out gaps in postpartum follow-up and care transitions. Statements also note disparities—some racial and ethnic groups experience higher APO prevalence and severity—reinforcing the value of capturing pregnancy history consistently and ensuring that preventive conversations continue beyond the final post-partum visit. Embedding reproductive history into risk assessment can help close these gaps by making it easier for primary care, cardiology, and obstetrics to share context over time.

Bottom line for providers and practices 

• Pregnancy history belongs in prevention. Treat GDM as a risk-enhancing signal alongside current risk factors and a contemporary risk estimate
• PREVENT provides a consistent baseline. Updated age ranges and lower thresholds mean more patients may qualify for earlier intervention
• A small toolkit adds clarity. Lp(a) once, ApoB selectively, and CAC for reclassification help fill in gaps when the picture is incomplete, especially in patients with a history of GDM 

How Labcorp can help 

Translating these updates into practice depends on how easily teams can order, interpret, and act on testing within their existing workflows. 

Labcorp supports this with tools designed for day-to-day care. Diagnostic Assistant® integrates into the EHR and flags when tests like Lp(a) or ApoB may add useful context. TestFinder provides clear, point-of-care guidance on specimen requirements, coding, and prep. 

Labcorp Link® and EHR integrations simplify ordering and tracking while delivering standardized, easy-to-interpret results. Together, these capabilities, along with a national patient collection network and validated methods, make PREVENT-aligned testing easier to implement in everyday practice without adding unnecessary steps.